Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025Presented ...
PharmiWeb

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...
ascopubs.org

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie ...

Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Purpose: To assess the efficacy and toxicity of ...
ascopubs.org

Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance

Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group PURPOSE: Rituximab was recently approved for use in relapsed, low-grade ...
Monthly Prescribing Reference

Rituximab Not Superior to Conventional Strategy for Eosinophilic Granulomatosis With Polyangiitis

Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis. HealthDay News — For patients with eosinophilic granulomatosis ...